Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
AbstractBACKGROUND: In advanced non-small cell lung cancer (NSCLC), the effectiveness of standard cytotoxic chemotherapy seems to have reached a 'plateau', and there is a continuous need for new treatments to further improve the prognosis. Cetuximab is a monoclonal antibody targeted at the epidermal growth factor receptor (EGFR) signalling pathway. Basically, it is designed to inhibit the growth and metastasis among other biological processes of cancer. In combination with chemotherapy, it has been evaluated as a first-line treatment for advanced NSCLC in some randomised controlled trials (RCTs), with inconsistent results.
All Author(s) ListYang Z.-Y., Liu L., Mao C., Wu X.-Y., Huang Y.-F., Hu X.-F., Tang J.-L.
Journal nameCochrane Database of Systematic Reviews
Volume Number11
Issue Number11
PublisherJohn Wiley & Sons Inc.
Place of PublicationUnited States
LanguagesEnglish-United Kingdom

Last updated on 2021-20-09 at 00:17